Answers are grounded in this paper and cite their sources.
Explores the causal role of ubiquitin in COVID-19 severity, suggesting therapeutic targets.
INTRODUCTION: The initial COVID-19 outbreak precipitated unprecedented health crises, with research impeded by containment protocols and the high mortality rate. While SARS-CoV-2 perturbs immune ubiquitin dynamics, the causal interplay between them remains uncharacterized. METHODS: We integrated multi-omics and Mendelian randomization (MR) approaches, including bidirectional and two-step MR, to assess causality between ubiquitination and initial COVID-19 severity and to determine whether immune cells mediate this relationship. Transcriptomic profiling, protein-protein interaction networks, immune-correlation analysis, and an elastic-net-derived prognostic model were employed to explore these interactions further and identify potential biomarkers. RESULTS: Bidirectional MR confirmed causal links between COVID-19 severity and ubiquitination, identifying 13 ubiquitin-related genes with altered expression. A two-step MR analysis of 731 immune cell traits revealed CD45RA+ CD8+ T cells as a mediator of severe COVID-19-induced ubiquitin dysregulation (mediation proportion: 5.797%). A prognostic model based on ISG15, UBE2B, and UBE2V1 demonstrated high predictive accuracy in the training cohort (AUC up to 0.977) and maintained good predictive power in the testing cohort (AUC: 0.672-0.819), with significant risk stratification (log-rank P < 0.001). DISCUSSION: We propose that ubiquitin may function as a causal immune orchestrator, shaping clinical outcomes in the initial phase of COVID-19. The derived ubiquitin gene prognostic model demonstrates potential for clinical risk stratification, while pathway enrichment and druginteraction analyses suggest opportunities for repurposing ubiquitin-related targets in COVID-19 therapy. CONCLUSION: This ubiquitin-centric framework advances precision management of severe COVID- 19, highlights the potential of ubiquitin-related targets for drug development, and establishes a multi-omics MR-based paradigm for future viral pandemics.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: